Jill Michaud, Pharm.D., BCPS. I have no actual or potential conflicts of interest related to this presentation

Similar documents
Ertugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy

Pharmacology. Update. Learning Objectives. Learning Objectives. for Advanced Practice Nurses

Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell

New Drug Update Biography. Objectives 2/18/2015. Wesley Lindsey, Pharm.D.

UPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY. Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center

PCSK9 INHIBITORS, ARNIS, FUNNY CHANNEL INHIBITORS: ARE YOU SURE THESE ARE REALLY CARDIAC DRUGS?

Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016

Chapter 1 The Reversing Agents

Diabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

The Many Faces of T2DM in Long-term Care Facilities

What s new with DOACs? Defining place in therapy for edoxaban &

Oral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action

TREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse

PCSK9 INHIBITORS NEW DRUGS IN CARDIOLOGY 7/6/ ANNUAL MEETING OBJECTIVES PCSK9 AND HYPERCHOLESTEROLEMIA PRESENTATION OUTLINE

A MONTHLY DOSE OF EDUCATION

Northern California Chapter ACP Update In Medicine I

What s New in Diabetes Medications. Jena Torpin, PharmD

True/False: Idarucizumab can be utilized for the management of bleeding associated with dabigatran.

What s New in Type 2 Diabetes? 2018 Diabetes Updates

Professional Practice Minutes December 7, 2016

The Death of Sulfonylureas? A Review of New Diabetes Medications

SGLT2 Inhibitors

Discuss the role of idarucizumab for the management of bleeding associated with dabigatran

DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!

New Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum

There have been important changes in diabetes care which may not be covered in undergraduate textbooks.

ADMINISTRATIVE CLINICAL Page 1 of 6

Antidiabetic Agents CHAPTER BIGUANIDES

GLP-1 receptor agonists for type 2 diabetes currently available in the U.S.

SGLT2 Inhibitors

Very Practical Tips for Managing Type 2 Diabetes

EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens

NEW DIABETES CARE MEDICATIONS

Soliqua 100/33. (insulin glargine, lixisenatide) New Product Slideshow

Newer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH

Help the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire

Do s and Don t of DOACs DISCLOSURE

Appendix 3 PCC Warfarin Reversal

Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion

Drug Class Review Newer Diabetes Medications and Combinations

Reversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017

Reversal Agents for NOACs (Novel Oral Anticoagulants)

Emergency Management of Patients on Direct Oral Anticoagulants (DOACs)

What s New in Type 2 Diabetes? 2018 Diabetes Updates

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

Diabetes Mellitus II CPG

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

Update on the Management of Cancer Associated VTE

SGLT2 Inhibitors

New Drug Update: 2018

Diabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital

Anticoagulation Task Force

Reversal of Anticoagulants at UCDMC

Update in Cardiology What s Hot in 2017?

Quick Guide MEDICATIONS 7th Edition Evan Sisson, Pharm.D., MHA, CDE

Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications

SGLT2 Inhibitors

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation

Direct Oral Anticoagulant Reversal

The Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015

Diabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs

INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA

Drug Class Monograph

Reversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016

Dept of Diabetes Main Desk

Medications for Treating Stroke

Xultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

ANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY

VICTOSA and Renal impairment DR.R.S.SAJAD

PRESCRIBER SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR THE HEALTHCARE PROVIDER

NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks

PATIENT SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR PATIENTS. Before starting on Soliris Important safety information for patients

CASE A2 Managing Between-meal Hypoglycemia

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol

GLYXAMBI (empagliflozin-linagliptin) oral tablet

Reversal of DOACs Breakthroughs and Their Aftermath

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM

Adlyxin. (lixisenatide) New Product Slideshow

Innovative, Unusual Therapies for DM-2: Insulin U-500, Bromocriptine, Colesevelam, and SGLT2 inhibitors. April 3 rd, 2014

Welcome to the New England QIN-QIO Medication Safety Webinar!

GLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks

Pharmacology. Definitions. Pharmacology Definitions 8/20/2013. Drug:

Non-insulin treatment in Type 1 DM Sang Yong Kim

Rebecca Newberry APRN MS CDE

Pharmacologic Agents for Treatment of Type 2 Diabetes

Before starting on Soliris.

Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018

10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI

Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015

What You Need to Know About ARZERRA (ofatumumab)

Do You Know Your SATs? (Sugar, Acid blockers, Thinners) Laura Habighorst RN CAPA CGRN Heartland SGNA Spring Conference 2014

Edoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor

Transcription:

Jill Michaud, Pharm.D., BCPS I have no actual or potential conflicts of interest related to this presentation

Focus New drugs you might use in the Emergency department New drugs patients might be on Indications Side effects

Not covering New oncology medications If the generic name ends in nib or mab good chance it is a cancer drug New Hepatitis C and HIV medications If the generic name ends in vir, likely for hepatitis C or HIV

Reference Favorite quick reference Centerwatch.com Least favorite Direct to consumer advertising Professional pharmaceutical reps

FDA approvals 45 new drugs in 2015 & 41 in 2014 10 therapeutic classes Plus new drug dosage forms or indications

Drug or Pokѐmon I ll display a name If you think it is a new drug hold up your pink card If you think it is a Pokemon hold up your green card

Novel Anticoagulants (NOCA) Factor Xa inhibitors rivaroxaban apixaban edoxaban approved Jan 2015 betrixaban expected to be approved late 2016 Direct Thrombin Inhibitors dabigatran

Novel Anticoagulants Side effects Bleeding! Increases the risks Age greater than 80 Weight less than 60 kg Renal dysfunction dabigatran, rivaroxaban, edoxaban Hepatic dysfunction - apixaban How long to hold before surgery Ideally 2-5 days But do patients need to bridge with a heparin product

Prothrombin Complex Concentrate Prothrombin Complex Concentrate (PCC) Approved for urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist In other words reverses warfarin Indicated if reversal of anticoagulation is needed within an hour Always administer vitamin K iv with PCC Expensive!

idarucizumab First true reversal agent for novel anticoagulants (dabigatran only) Monoclonal antibody fragment targeted specifically for dabigatran Fun fact binds 350 times stronger than Thrombin IV 5 grams provided as 2 separate vials of 50 ml each

Andexanet alfa Inactivated factor Xa Binds and reverses anti-xa inhibitors Rivaroxaban, apixaban, edoxaban, betrixaban Not approved by the FDA yet

ivabradine Indicated to reduce the risk of hospitalization due to worsening heart failure In stable patients taking beta-blockers at highest dose or do not tolerate beta blockers Ejection Fraction less than 35% Side effects: Bradycardia Teratogenic a. fib

Sacubitril + Valsartan Sacubitril neprilysin inhibitor Valsartan antigiotensin receptor blocker Indicated to reduce risk of death and hospitalization from heart failure Side effects dizziness, hypotension, hyperkalemia, cough, renal failure

Alirucumab Evolcumab Proprotein Convertase Subtilisin Kexin Type 9 inhibitor antibody PCSK9 Indicated for lowering LDL cholesterol who have maxed out on statins Subcutanous injection every 2 weeks Side effects allergic reactions or injection site reactions

patiromer Potassium binder for treatment of hyperkalemia NOT for emergency use as has a delayed onset of action Binds potassium in the gut Side effects: constipation

dapagliflozin empagliflozin canagliflozin SGLT-2 inhibitor (sodium glucose cotransporter type 2) Inhibits reabsorption of glucose in the kidney, increasing excretion of glucose in the kidney Used alone or in combination with metformin 2015 FDA warning of ketoacidosis

albiglutide dulaglutide lirglutide GLP-1 agonist Glucogon-like peptide receptor agonist Slows gastric emptying Increases glucose dependent insulin release Once weekly subcutaneous injection

Insulin glargine 300units/ml Regular insulin 500units/ml pen Concentrated insulin products Watch doses!!!

insulin deguldec insulin degludec/insulin aspart Long acting once daily insulin and combination long/short acting Available in pens 100 unit/ml 200 unit/ml Watch doses! Hypoglycemia will be long lasting

ceftazidime/avibactam ceftolozane/tazobactam Combination of a cephalosporin and beta-lactamase inhibitor Beta lactamase inhibitor is to overcome resistance For complicated intra abdominal infections or complicated urinary tract infections Side effects: nausea/diarrhea

oritavancin delbavancin Lipoglycopeptide antibacterial For gram-positive infections oritavancin single dose given over 3 hr infusion equivalent to 7 10 day course of vancomycin delbavancin weekly infusion Reserved for resistant gram positive organisms and long courses

fidaxomicin Treatment of Chlostridium difficile associate diarrhea Not inferior to vancomycin Use if patient fails on vancomycin Side effects: nausea, vomiting, abdominal pain Expensive! $4,000 for a 10 day course

flibanserin Female Viagra Indicated for hypoactive sexual desire disorder Daily at bedtime Contraindicated with alcohol increases risk of hypotension and syncope Side effects: hypotension, syncope, accidental injury, CNS depression

deoxycholic acid When injected into subcutaneous fat, cause the destruction of fat cells Used to aid breakdown and adsorption of submental fat Subcutaneous injection Side effects: pain, numbness, injection site edema, induration

isavuconazole isavuconazole Treatment of invasive aspergillosis and mucormycosis Triazole antifungal

naloxegol Treats constipation resulting from opioid use in adults with chronic non-cancer pain Take on an empty stomach an hour before or 2 hours after a meal Side effects: abdominal pain, diarrhea, nausea, flactulance

Meningococcal Group B Vaccine Prevent invasive meningococcal disease This is in addition to the current meningococcal vaccines Group B has been the strain of the meningitis outbreak on college campus over the past 2 years

Questions?